Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intra-Arterial Treatment of Medium-sized Primary Vessel Occlusions: A Randomized Controlled Trial (IMP-ACT)Embedded in A Multi-faCtorial,mulTi-arm, Multi-staGe,Randomised,gLOBal Adaptive pLatform Trial for Stroke NCT06352632

NCT07906275 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT07906275 Not yet recruiting Phase 3 800 participants (estimated) Started 2026 4 sites

Follow this trial by email Email me the PDF

Get the NCT07906275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started December 2026. Interventional study, Phase 3, 800 participants (estimated). Lead sponsor University of Calgary; Canada. Primary measure: A change of functional dependence analyzed across the whole distribution of outcomes assessed...

How it compares

263 similar trials: same condition (Ischemic Stroke) and phase

Enrollment

This trial
800
Middle half
222 to 991
Median
520
Trials with a value
263

Months from start to completion

This trial
51.5
Middle half
22 to 44.2
Median
29.6
Trials with a value
256

Sites

This trial
4
Middle half
1 to 22
Median
1
Trials with a value
241
Posted results or a linked paper 56% 148 of 263 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Intra-Arterial Treatment of Medium-sized Primary Vessel Occlusions: A Randomized Controlled Trial (IMP-ACT)Embedded in A Multi-faCtorial,mulTi-arm, Multi-staGe,Randomised,gLOBal Adaptive pLatform Trial for Stroke NCT06352632
Lead sponsor
University of Calgary
Phase
Phase 3
Overall status
Not yet recruiting
Start date
December 15, 2026
Completion date
March 31, 2031
Enrollment
800 (estimated)
Sites
4

Conditions

MeSH condition names; the registry's own terms follow.

Ischemic Stroke

Registry terms: medium vessel occlusion, stroke, acute ischemic

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
No
Study type
Interventional
Sites
4
Countries
Canada
Lead sponsor
University of Calgary

Arms

As registered; 3 arms.

Registered arms
Arm Type Interventions
Control Placebo comparator Intravenous Thrombolysis
Show registry wording

usual care - intravenous thrombolysis (0.18mg/kg or 0.25mg/kg of tenecteplase) if eligible, plus usual stroke unit care.

Mechanical EVT Active comparator Mechanical Endovascular Thrombectomy
Show registry wording

Tools and technique left to the discretion of the operator; intra-arterial thrombolytic drugs must not be administered.

Mechanical EVT followed by adjunctive intra-arterial thrombolysis Active comparator Mechanical Endovascular Thrombectomy, Tenecteplase/Alteplase- depending upon availability at each treating centre
Show registry wording

microcatheter injection of tenecteplase up to 0.0625 mg/kg (maximum 6.25 mg) or alteplase up to 0.225 mg/kg (maximum 22.5 mg) over 5-10 minutes from a proximal, safe microcatheter position in the affected arterial territory, with agent selected according to local availability.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
A change of functional dependence analyzed across the whole distribution of outcomes assessed on the modified Rankin Scale (mRS), From enrollment to the Day 90 assessment - Day 90 outcomes are assessed in a blinded manner
Show registry wording

Modified Rankin Scale (mRS) -which scores of 0 to 1 indicate a favourable outcome without or with symptoms but no disability, scores of 2 to 5 indicate increasing levels of disability (and dependency), and a score of 6 indicates death.

Lead sponsor's other trials

University of Calgary, most recent start first.

Similar trials

Same condition (Ischemic Stroke) and phase, most recent start first.